View Older Stories View More Recent Stories

Mar 2, 2026 10:59AM Ascendis Pharma (ASND) PT Raised to $260 at Wolfe Research
Mar 2, 2026 10:38AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
Mar 2, 2026 10:03AM Ascendis Pharma (ASND) PT Raised to $324 at Evercore ISI
Mar 2, 2026 09:19AM Stifel Reiterates Buy Rating on Ascendis Pharma (ASND) as Yuviwel Approved for Achondroplasia
Mar 2, 2026 04:55AM Ascendis Pharma (ASND) PT Raised to $255 at Goldman Sachs
Feb 23, 2026 08:58AM RBC Capital: 'KOL Sees Ascendis Pharma's (ASND) Commercial Momentum Continuing Steadily From Here'
Feb 12, 2026 01:54PM Ascendis Pharma (ASND) PT Raised to $300 at Cantor Fitzgerald
Feb 12, 2026 10:03AM Ascendis Pharma (ASND) PT Raised to $325 at Stifel Following Q4 Results
Feb 12, 2026 07:41AM BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data
Feb 11, 2026 04:01PM Ascendis Pharma (ASND) Misses Q4 EPS by 40c
Jan 22, 2026 11:56AM Ascendis Pharma (ASND) Strength Tied to Unconfirmed M&A Chatter
Jan 20, 2026 05:30AM Ascendis Pharma (ASND) PT Raised to $250 at RBC Capital
Jan 12, 2026 08:26AM Ascendis (ASND) Reiterated at Buy by Stifel on Yprvipath Beat
Jan 12, 2026 08:18AM Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald
Jan 9, 2026 07:10AM Ascendis Pharma (ASND) Reiterated at Buy by Stifel After Release of June Study Data
Jan 8, 2026 04:04PM Ascendis reports positive 52-week trial data for achondroplasia treatment
Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC
Jan 7, 2026 09:13AM TD Cowen on Ascendis Pharma (ASND): 'Physician Survey Shows Smooth Sailing For Yorvipath'
Dec 12, 2025 03:22PM Ascendis Pharma (ASND) Gains Appear to be Tied to Unconfirmed M&A Chatter
Nov 26, 2025 07:00AM Ascendis Pharma's (ASND) PDUFA Extension a Minor Issue - Cantor Fitzgerald
Nov 26, 2025 06:48AM Ascendis Pharma's (ASND) PDUFA Disclosure Removes Near-Term Stock Upside - Stifel
Nov 24, 2025 08:53AM TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)
Nov 17, 2025 04:10PM Wolfe Research Starts Ascendis Pharma (ASND) at Outperform
Nov 17, 2025 04:01PM Ascendis Pharma publishes pivotal trial results for achondroplasia drug
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 13, 2025 06:55AM Ascendis Pharma (ASND) Looks at Decreased FY2025-26 Revenues - Cantor Fitzgerald
Nov 13, 2025 04:04AM Goldman Sachs on Ascendis Pharma (ASND): 'in transition to profitability'
Nov 12, 2025 04:05PM Ascendis Pharma (ASND) Misses Q3 EPS by 72c
Nov 7, 2025 08:31AM Ascendis Pharma reports sustained kidney function improvements with YORVIPATH
Oct 16, 2025 04:06PM Raymond James Starts Ascendis Pharma (ASND) at Strong Buy, PT $271, 'We see a high conviction path to a $4B+ top line'
Oct 13, 2025 07:21AM Cantor Fitzgerald Raises Ascendis Pharma (ASND) PT to $254, Sees Steady New Patient Adds
Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview
Oct 8, 2025 04:01PM Ascendis submits European approval application for achondroplasia drug
Sep 24, 2025 06:00AM Buy weakness in this pharma stock: Wells Fargo
Sep 23, 2025 08:59AM UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
Sep 8, 2025 09:46AM BofA Securities on Ascendis Pharma (ASND): 'well positioned to capture market share'
Aug 20, 2025 08:25AM Ascendis Pharma (ASND) PT Raised to $260 at JPMorgan
Aug 8, 2025 10:13AM Ascendis Pharma (ASND) PT Raised to $203 at Cantor Fitzgerald
Aug 8, 2025 08:40AM Ascendis Pharma (ASND) PT Raised to $230 at RBC Capital
Aug 8, 2025 08:16AM Ascendis Pharma (ASND) PT Raised to $227 at TD Cowen
Aug 8, 2025 05:42AM Ascendis Pharma (ASND) PT Raised to $227 at BofA Securities
Aug 8, 2025 05:29AM Ascendis Pharma (ASND) PT Raised to $285 at Evercore ISI
Aug 8, 2025 05:23AM Ascendis Pharma (ASND) PT Raised to $250 at Goldman Sachs
Aug 7, 2025 04:04PM Ascendis Pharma (ASND) Tops Q2 EPS by 45c
Aug 4, 2025 07:09AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
Jul 28, 2025 07:00AM SKYTROFA receives FDA approval for adult growth hormone deficiency
Jul 14, 2025 04:01PM Ascendis Pharma reports 3-year data on hypoparathyroidism treatment
Jul 8, 2025 02:54PM Ascendis Pharma (ASND) 1K contracts of September 150 puts active
Jul 2, 2025 04:17PM Morgan Stanley Assumes Ascendis Pharma (ASND) at Overweight
Jun 25, 2025 10:13AM UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
View More Recent Stories View Older Stories